<DOC>
	<DOC>NCT01087762</DOC>
	<brief_summary>The study is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of two dose regimens of Certolizumab Pegol (CZP) in subjects with active axial Spondyloarthritis (axial SpA).</brief_summary>
	<brief_title>Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis</brief_title>
	<detailed_description />
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Spondylarthropathies</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Documented diagnosis of adultonset axial Spondyloarthritis (SpA) of at least 3 months' duration as defined by the specified Assessment of Spondyloarthritis International Society (ASAS) criteria Active disease as defined by: Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score ≥ 4 Back pain ≥ 4 on a 0 to 10 Neurobehavioral Rating Scale (NRS) (from BASDAI item 2) CReactive Protein (CRP) &gt; ULN (Upper Limit of Normal) and/or current evidence (ie, within the last 3 months from Screening) for Sacroiliitis on Magnetic Resonance Imaging (MRI) as defined by Assessment of Spondyloarthritis International Society (ASAS) criteria Intolerance to or inadequate response to at least 1 Nonsteroidal AntiInflammatory Drug (NSAID) Presence of total Spinal Ankylosis ("bamboo spine") Diagnosis of any other Inflammatory Arthritis Prior treatment with any experimental biological agents for treatment of Axial Spondyloarthritis (SpA) Exposure to more than 1 TNFantagonist or to more than 2 previous biological agents for Axial Spondyloarthritis (SpA) History of or current chronic or recurrent infections High risk of infection Recent live vaccination Concurrent malignancy or a history of malignancy Class III or IV congestive heart failure New York Heart Association (NYHA) Demyelinating disease of the central nervous system Female subjects who are breastfeeding, pregnant or plan to become pregnant during the study or within 3 months following the last dose of the investigational product Subjects with any other condition which, in the investigator's judgment, would make the subject unsuitable for inclusion in the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Certolizumab Pegol</keyword>
	<keyword>Cimzia</keyword>
</DOC>